Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Sort descending Date Submission Received Date Recommendation Issued
Bavencio Avelumab metastatic Merkel Cell Carcinoma (mMCC) Reimburse with clinical criteria and/or conditions Complete
Stivarga Regorafenib Unresectable Hepatocellular Carcinoma (HCC) Reimburse with clinical criteria and/or conditions Complete
Kisqali Ribociclib Advanced or Metastatic Breast Cancer Reimburse with clinical criteria and/or conditions Complete
Dysport Therapeutic abobotulinumtoxinA lower limb spasticity Reimburse with clinical criteria and/or conditions Complete
Duodopa Levodopa / carbidopa (Drug Plan Submission) Parkinson's disease Reimburse with clinical criteria and/or conditions Complete
Orkambi lumacaftor/ivacaftor Cystic Fibrosis, F508del CFTR mutation in patients 6 years and older Do not reimburse Complete
Fasenra benralizumab Asthma, severe eosinophilic Reimburse with clinical criteria and/or conditions Complete
Inlyta (RFA) Axitinib Metastatic Renal Cell Carcinoma N/A Complete
Ocrevus ocrelizumab multiple sclerosis, relapsing Reimburse with clinical criteria and/or conditions Complete
Abraxane Nab-paclitaxel Metastatic Pancreatic Cancer Reimburse with clinical criteria and/or conditions Complete